These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30854190)

  • 21. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
    Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
    Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
    Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
    Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabidiol in the Treatment of Epilepsy.
    von Wrede R; Helmstaedter C; Surges R
    Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol in treatment of refractory epileptic spasms: An open-label study.
    Herlopian A; Hess EJ; Barnett J; Geffrey AL; Pollack SF; Skirvin L; Bruno P; Sourbron J; Thiele EA
    Epilepsy Behav; 2020 May; 106():106988. PubMed ID: 32169600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of cannabis for treating children with refractory epilepsy.
    Neale M
    Nurs Child Young People; 2017 Sep; 29(7):32-37. PubMed ID: 29115760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
    Birnbaum AK; Karanam A; Marino SE; Barkley CM; Remmel RP; Roslawski M; Gramling-Aden M; Leppik IE
    Epilepsia; 2019 Aug; 60(8):1586-1592. PubMed ID: 31247132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
    Hausman-Kedem M; Menascu S; Kramer U
    Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
    Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
    Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of cannabidiol in the treatment of epilepsy.
    Mazurkiewicz-Bełdzińska M; Zawadzka M
    Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidiolex-induced skin rash.
    Singh J; Antimisiaris MF
    Epileptic Disord; 2020 Aug; 22(4):511-514. PubMed ID: 32729550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.
    Warren PP; Bebin EM; Nabors LB; Szaflarski JP
    Neurocase; 2017; 23(5-6):287-291. PubMed ID: 29063814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy.
    Thompson MD; Martin RC; Grayson LP; Ampah SB; Cutter G; Szaflarski JP; Bebin EM
    Epilepsy Behav; 2020 Oct; 111():107299. PubMed ID: 32759071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
    Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).
    Klein BD; Jacobson CA; Metcalf CS; Smith MD; Wilcox KS; Hampson AJ; Kehne JH
    Neurochem Res; 2017 Jul; 42(7):1939-1948. PubMed ID: 28478594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
    Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
    Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.
    Kaplan EH; Offermann EA; Sievers JW; Comi AM
    Pediatr Neurol; 2017 Jun; 71():18-23.e2. PubMed ID: 28454984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol in canine epilepsy.
    Potschka H; Bhatti SFM; Tipold A; McGrath S
    Vet J; 2022 Dec; 290():105913. PubMed ID: 36209995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Epidiolex® (Cannabidiol) on seizure-related emergency department visits and hospital admissions: A retrospective cohort study.
    Abu-Sawwa R; Chase A; Fowowe O; Park Y
    Epilepsy Behav; 2022 Feb; 127():108538. PubMed ID: 35051868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.